Summit Therapeutics (SMMT) Accumulated Depreciation & Amortization: 2019-2024
- Summit Therapeutics' Accumulated Depreciation & Amortization rose 7.29% to $1.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $4.5 million, marking a year-over-year decrease of 0.24%. This contributed to the annual value of $1.1 million for FY2024, which is 7.29% up from last year.
- As of Q4 2024, Summit Therapeutics' Accumulated Depreciation & Amortization stood at $1.1 million, which was up 7.29% from $1.0 million recorded in Q4 2023.
- In the past 5 years, Summit Therapeutics' Accumulated Depreciation & Amortization ranged from a high of $1.3 million in Q4 2022 and a low of $1.0 million during Q4 2021.
- Over the past 3 years, Summit Therapeutics' median Accumulated Depreciation & Amortization value was $1.1 million (recorded in 2024), while the average stood at $1.2 million.
- Per our database at Business Quant, Summit Therapeutics' Accumulated Depreciation & Amortization grew by 25.19% in 2022 and then dropped by 19.66% in 2023.
- Quarterly analysis of 5 years shows Summit Therapeutics' Accumulated Depreciation & Amortization stood at $1.1 million in 2020, then decreased by 8.24% to $1.0 million in 2021, then rose by 25.19% to $1.3 million in 2022, then decreased by 19.66% to $1.0 million in 2023, then rose by 7.29% to $1.1 million in 2024.
- Its last three reported values are $1.1 million in Q4 2024, $1.0 million for Q4 2023, and $1.3 million during Q4 2022.
